Printer Friendly

CANGUARD AND DEPRENYL RESEARCH HAVE COURT DATE ON APRIL 30

 CANGUARD AND DEPRENYL RESEARCH HAVE COURT DATE ON APRIL 30
 VANCOUVER, British Columbia, April 8 /PRNewswire/ -- Canguard Health Technologies Inc. (Vancouver: CGD) announced today that the lawsuit with Deprenyl Research Ltd. (NASDAQ: DEPLF, Toronto: DEP) returns to court on April 30, 1992 and has been set down for a two-day hearing. The Deprenyl Group has accused the Canguard Group of infringing a process patent for making selegiline hydrochloride (L-deprenyl hydrochloride), the active ingredient in the Deprenyl Group's ELDEPRYL and the Canguard Group's PARKINYL.
 The allegations have been denied by the Canguard Group which uses a different, non-infringing process to prepare selegiline hydrochloride and believes it has sufficient evidence to prove its position. Moreover, the Canguard Group is seeking to have the case dismissed since the Deprenyl Group has presented no evidence of patent infringement.
 -0- 4/8/92
 /CONTACT: John B. Armstrong, president of Canguard, 604-682-1777/
 (DEPLF CGD. DEP.) CO: Canguard Health Technologies Inc.; Deprenyl Research Ltd. ST: British Columbia IN: SU:


KJ -- LA034 -- 6447 04/08/92 17:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 8, 1992
Words:171
Previous Article:BET PRESENTS EXCLUSIVE INTERVIEW WITH MARION BARRY APRIL 14
Next Article:FLORIDA REGIONAL STOCK REPORT FOR WEDNESDAY, APRIL 8


Related Articles
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO COMMENTS ON DEPRENYL RESEARCH LTD. PRESS RELEASE
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO LAWSUIT ANNOUNCED IN PRESS ON DEC. 3
CANGUARD HEALTH TECHNOLOGIES ANNOUNCES LAWSUIT UPDATE
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
CANGUARD HEALTH TECHNOLOGIES ADJOURNMENT AGREEMENT
CANGUARD HEALTH TECHNOLOGIES RESPONSE TO DEPRENYL RELEASE
CANGUARD AND DEPRENYL RESEARCH LAWSUIT ADJOURNED TODAY; NO RESTRICTIONS IMPOSED ON CANGUARD
CANGUARD SERVES NOTICE OF MOTION, FINAL AFFIDAVITS ON DEPRENYL RESEARCH; ANNOUNCES NEW BUSINESS DEVELOPMENTS
CANGUARD DEFEATS DEPRENYL RESEARCH ON CONTEMPT CHARGE
CANGUARD HEALTH TECHNOLOGIES INC. - ANNOUNCES DEPRENYL RESEARCH LTD. HAS REQUESTED POSTPONEMENT IN LAWSUIT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters